Growth vs. Profit: Why Zydus Won't Bank on Q1's Bottom Line

Zydus delivered double-digit revenue growth of 22% YoY and held EBITDA margin at 24.1%, meeting its FY27 guidance. But net profit collapsed 34.9% YoY to ₹990.2 Cr—a jaw-dropping gap that sent the stock up 1.18% on day 1, then fading 4.69% by day 3 as the market digested the headwind. The reconciliation: acquisition amortization (Assertio, Zylidac, Mirabegron settlement) accounts for ~80% of the year-over-year cost rise, alongside pre-launch investment spend on Saro and increased depreciation from acquisitions. This is not operational deterioration; it is the cost of transformation. Mirabegron licensing amortization runs through Q1 FY28, meaning the drag continues. Management did not lead the call with this severity; analysts had to probe deeply to extract it.

Zydus is executing a deliberate shift from commodity generics to branded specialty. Three strategic moves signaled: (1) Saroglitazar (Saro) is now the flagship US specialty asset, with FY28 launch expected (FDA priority review granted for Primary Biliary Cholangitis). First 2 years are investment phase—no material revenue expected in year 1. Peak sales pegged $200–300M (conservative) to $400M+ (optimistic); the 100%+ spread signals internal uncertainty on addressable market. Expanded indication trial (marginal ALP) starting, adding 2–3 year optionality. (2) US specialty platform strengthened via acquisitions: Assertio (Rolvedon biosimilar ramping $15–20M/qtr Q2 onwards), Nufymco (Ranibizumab biosimilar), and 505(b)(2) cluster ($60–70M). Branded revenue share in US now 10%, targeting 15%+ by year-end. (3) Capex spike to ₹1,500–₹1,600 Cr FY27 (2x historical ~₹700–800 Cr) for SEZ-3 completion, facility expansions, new R&D center, CAR-T facility, vaccine DS capacity, wellness land acquisition. Sustainability post-FY27 not detailed; likely normalizes once facilities ready.

The price action is the market's own verdict on the quarter. Day-1 pop of +1.18% (delivery 49.5%) faded to -4.69% by day 3 as reality set in: PAT down 35% despite revenue beat, and capex/investment phase headwinds are real. Stock now at ₹1,131.5, down 6.1% from all-time high of ₹1,205, but up 35.4% from 52-week low of ₹835.5. Trading above 20-, 50-, and 200-day moving averages; RSI 56.5 signals neutral momentum. Most tellingly: FII ownership ticked down 0.07 percentage points QoQ to 6.88%—a quiet bearish signal despite price recovery near ATH. Institutions are trimming into strength, signaling caution on execution risk. DII added 0.07pp to 11.27%; promoter stake locked at 75%. Float is tight and FII skepticism is notable.

Adjusted EBITDA margin (backing out acquisition amortization and Mirabegron royalty burden) is the single most important metric going forward. If adjusted EBITDA margin stays at 24%+ and grows as Saro ramps and capex normalizes, management's 28–30% target by FY30 is credible. If adjusted margin compresses below 24%, the transformation thesis is at risk. This is the hold-or-sell trigger for the next 4 quarters.